Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 5115

Provisional Schedule

Committee meeting 06 August 2024
Expected publication 16 October 2024

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group School of Health and Related Research (ScHARR), University of Sheffield


Companies sponsors Bristol-Myers Squibb (fedratinib)
Others Department of Health and Social Care
  NHS England
Patient carer groups Blood Cancer UK
  Leukaemia Care
  MPN Voice
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Associated public health groups None
Comparator companies GlaxoSmithKline (momelotinib) (confidentiality agreement signed, participating)
  Novartis (ruxolitinib) (confidentiality agreement signed, participating)
  Masters Pharmaceuticals (hydroxycarbamide) (confidentiality agreement not signed, not participating)
  Medac UK (hydroxycarbamide) (confidentiality agreement not signed, not participating)
  Neon Healthcare Ltd (hydroxycarbamide) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
08 January 2024 Invitation to participate
20 October 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early January 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
11 September 2023 - 02 October 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
04 July 2023 In progress. Topic in appraisal.

For further information on our processes and methods, please see our CHTE processes and methods manual